Mapping the landscape of genomic cancer signals in the blood
The Circulating Cell-free Genome Atlas (CCGA) Study is a prospective, observational, longitudinal, study designed to characterize the landscape of genomic cancer signals in the blood of people with and without cancer. The study enrolled approximately 15,000 participants across 142 sites in the United States and Canada, and includes both people who had cancer at the time of enrollment (newly diagnosed, and not yet received treatment) and people who did not have a known cancer diagnosis. Planned follow-up for all participants is at least five years to collect clinical outcome data.